Cargando…

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery

Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine kinase inhibitors. In this case report, we show the durable clinical benef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gouda, Mohamed A., Janku, Filip, Somaiah, Neeta, Hunt, Kelly K., Yedururi, Sireesha, Subbiah, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511119/ https://www.ncbi.nlm.nih.gov/pubmed/37736254 http://dx.doi.org/10.18632/oncoscience.586

Ejemplares similares

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
por: Thirasastr, Prapassorn, et al.
Publicado: (2023)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
por: Janku, F., et al.
Publicado: (2022)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
por: Lostes-Bardaji, M. Julia, et al.
Publicado: (2021)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Whole-genome and Epigenomic Landscapes of Malignant Gastrointestinal Stromal Tumors Harboring KIT Exon 11 557–558 Deletion Mutations
por: Ohshima, Keiichi, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib
por: Brackert, Sandra, et al.
Publicado: (2023)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023)

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
por: Li, Xiaoyan, et al.
Publicado: (2022)

Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11
por: Gregory-Bryson, Emmalena, et al.
Publicado: (2010)

The KIT Exon 11 Stop Codon Mutation in Gastrointestinal Stromal Tumors: What Is the Clinical Meaning?
por: Michelucci, Angela, et al.
Publicado: (2013)

Mutations in c‐kit Gene Exons 9 and 13 in Gastrointestinal Stromal Tumors among Japanese
por: Sakurai, Shinji, et al.
Publicado: (2001)

Analysis of C-Kit Exon 9, Exon 11 and BRAFV600E Mutations Using Sangers Sequencing in Gastrointestinal Stromal Tumours
por: Madhala, Divya, et al.
Publicado: (2020)

Computed tomography texture-based models for predicting KIT exon 11 mutation of gastrointestinal stromal tumors
por: Guo, Chuangen, et al.
Publicado: (2023)

Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
por: Huang, Shaoqing, et al.
Publicado: (2022)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Gastrointestinal stromal tumors: associations between contrast-enhanced CT images and KIT exon 11 gene mutation
por: Liu, Xijiao, et al.
Publicado: (2021)

Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors
por: Shen, Yan‐Ying, et al.
Publicado: (2020)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
por: Schöffski, Patrick, et al.
Publicado: (2022)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

SKP2 High Expression, KIT Exon 11 Deletions, and Gastrointestinal Bleeding as Predictors of Poor Prognosis in Primary Gastrointestinal Stromal Tumors
por: Lv, Ang, et al.
Publicado: (2013)

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
por: Yeh, Chun-Nan, et al.
Publicado: (2017)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Clinical-radiomics-based treatment decision support for KIT Exon 11 deletion in gastrointestinal stromal tumors: a multi-institutional retrospective study
por: Zhang, Yu, et al.
Publicado: (2023)

Molecular landscape and clinical significance of exon 11 mutations in KIT gene among patients with gastrointestinal stromal tumor: a retrospective exploratory study
por: Zhao, Ruihua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oomducfoh55o2pqojodni1kmnl